New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin

PfizerPfizer Consumer Healthcare has announced the launch of Centrum®VitaMints®, a great-tasting and easy-to-take multivitamin that offers consumers the essential nutrients they can enjoy like a mint, from Centrum®, a brand they know and trust.

"Americans want to live well - they want to eat right and exercise often - however they are often short on the time needed to support an active, healthy lifestyle," said Bahar Takhtehchian, lifestyle and wellness expert. "By offering a multivitamin in a flavor many consumers love, Centrum® VitaMints® give consumers an on-the-go option they enjoy like a mint that helps support energy, immunity and metabolism."

Centrum® VitaMints® is a refreshing and complete multivitamin that provides a more enjoyable experience for consumers to get essential nutrients, and joins other Centrum products to form one of the most comprehensive lines of multivitamins on the market.

"Pfizer Consumer Healthcare is committed to bringing a range of exciting new Centrum multivitamin formulas to market that seamlessly fit into Americans' everyday lives, including Centrum® VitaMints®, a surprisingly and refreshing mint tasting multivitamin that breaks through in a category traditionally known for tablets and gummies," said Robert Uccardi, Director for Centrum, Pfizer Consumer Healthcare.

Centrum® VitaMints® in Cool Mint flavor is intended for adults, and includes such key nutrients as Vitamins A, C, D and E, amongst others. Serving size is two minty chewables daily which can be taken with or without food or water. When it comes to any consumer health product, consumers should always read and follow the directions on the product label, including the recommended daily servings.

Available at major retailers nationwide and online, Centrum® VitaMints® is sold in 60- and 120-count bottles.

It is important to note, dietary supplements are not intended to diagnose, treat, cure or prevent any disease but rather help consumers fill daily dietary gaps.

About Centrum®
With over 35 years of nutritional science expertise, Centrum® multivitamins remain the multivitamin chosen for multiple landmark studies on long-term health benefits and continue to be the most-clinically studied, most-preferred and most-doctor and pharmacist recommended multivitamin brand in America. Centrum® is a complete multivitamin that delivers a combination of essential vitamins and minerals that help support overall health and well-being. Centrum® multivitamins support multiple health benefits such as energy, immunity, heart health, bone health, eye and skin health. To see what nutrients are inside Centrum®, and learn more about our product formulations, please visitwww.Centrum.com (link is external).

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...